ProPhase Labs, Inc. Adjustments to Additional Paid in Capital, Other
ProPhase Labs, Inc. (PRPH) reported Adjustments to Additional Paid in Capital, Other of -$179.00 thousand for the 9-month period ending 2017-09-30, per its 10-Q/A filed 2018-08-20.
Discontinued › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalOther · last filed 2018-08-20
- ProPhase Labs, Inc. adjustments to additional paid in capital, other for the quarter ending 2017-09-30 was -$136.00K.
- ProPhase Labs, Inc. adjustments to additional paid in capital, other for the quarter ending 2017-06-30 was -$30.00K.
- ProPhase Labs, Inc. adjustments to additional paid in capital, other for the quarter ending 2017-03-31 was -$13.00K.
| Period end | Adjustments to Additional Paid in Capital, Other 3 month | Adjustments to Additional Paid in Capital, Other 6 month | Adjustments to Additional Paid in Capital, Other 9 month |
|---|---|---|---|
| 2017-09-30 | -$136.00K derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2018-08-20 | -$166.00K derived: sum of 2 quarters · filed 2018-08-20 | -$179.00K 10-Q/A · filed 2018-08-20 |
| 2017-06-30 | -$30.00K derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2018-08-20 | -$43.00K 10-Q/A · filed 2018-08-20 | |
| 2017-03-31 | -$13.00K 10-Q/A · filed 2018-08-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |